Soluble tumor necrosis factor receptor and other soluble immunosuppressive blood factors (sTNFRs/SIBFs)

Soluble tumor necrosis factor receptors (sTNFRs) and related soluble immunosuppressive blood factors are circulating proteins derived from the proteolytic cleavage of membrane-bound receptors or through alternative splicing. In healthy individuals, these factors serve as natural regulators of the immune system by acting as decoy receptors that neutralize pro-inflammatory cytokines like TNF-alpha, thereby preventing excessive tissue damage. However, in pathological states such as advanced cancer, tumors often exploit this mechanism by overproducing or inducing the shedding of these receptors to create an immunosuppressive environment that facilitates 'immune escape.' By neutralizing the cytokines necessary for an effective anti-tumor response, these soluble factors hinder the efficacy of both the innate immune system and various immunotherapies. Consequently, they are studied both as biomarkers for disease progression and as targets for removal via extracorporeal therapies to restore the patient's immune competence.

Other names

Soluble TNF receptorssTNFR1sTNFR2Soluble cytokine receptorsImmunosuppressive plasma factors

These factors typically act as decoy receptors that bind to and neutralize circulating cytokines like TNF-alpha, thereby preventing them from binding to cell-surface receptors and initiating an immune response. In the context of cancer, they contribute to 'immune escape' by neutralizing the body's anti-tumor inflammatory response. Therapeutic strategies often involve either using recombinant versions to dampen inflammation or removing them via apheresis to restore immune surveillance in oncology.